<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Peroxisome proliferator-activated receptors (PPAR) regulate the expression of genes involved in <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism, energy production, and <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Their role in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-reperfusion (I/R) is less clear, although research indicates involvement of PPARs in some forms of preconditioning </plain></SENT>
<SENT sid="2" pm="."><plain>This study aimed to explore the effects of PPAR-α activation on the I/R injury and potential cardioprotective downstream mechanisms involved </plain></SENT>
<SENT sid="3" pm="."><plain>Langendorff-perfused hearts of rats pretreated with the selective PPAR-α <z:chebi fb="4" ids="48705">agonist</z:chebi> WY-14643 (WY, <z:chebi fb="0" ids="32509">pirinixic acid</z:chebi>; 3 mg·(kg body mass)·day(-1); 5 days) were subjected to 30 min <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> - 2 h reperfusion with or without the phosphatidylinositol 3-kinase (PI3K)-Akt inhibitor <z:chebi fb="0" ids="52289">wortmannin</z:chebi> for the evaluation of functional (left ventricular developed pressure, LVDP) recovery, <z:mpath ids='MPATH_124'>infarct</z:mpath> size (IS), and reperfusion-induced <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>A 2-fold increase in baseline PPAR-α <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels (qPCR) in the WY-treated group and higher post-I/R PPAR-α levels compared with those in untreated controls were accompanied by similar changes in the expression of PPAR-α target genes PDK4 and mCPT-1, regulating <z:chebi fb="105" ids="17234">glucose</z:chebi> and fatty acid metabolism, and by enhanced Akt phosphorylation </plain></SENT>
<SENT sid="5" pm="."><plain>Post-ischaemic LVDP restoration in WY-treated hearts reached 60% ± 9% of the pre-ischaemic values compared with 24% ± 3% in the control hearts (P &lt; 0.05), coupled with reduced IS and incidence of <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> that was blunted by <z:chebi fb="0" ids="52289">wortmannin</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Results indicate that PPAR-α up-regulation may confer preconditioning-like protection via metabolic effects </plain></SENT>
<SENT sid="7" pm="."><plain>Downstream mechanisms of PPAR-α-mediated cardioprotection may involve PI3K-Akt activation </plain></SENT>
</text></document>